Study S001629

A Phase 3, Multi-center, Randomized, Double-Blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Adults With Overweight or Obesity (SLIMMER)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05813795
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: COMPLETED
Enrollment: 664
Start: 2023-04-05
Primary completion: 2024-06-20
Lead sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Conditions: Weight Management
Interventions: DRUG:Ecnoglutide Low Dosage; DRUG:Ecnoglutide Medium Dosage; DRUG:Ecnoglutide High Dosage; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percent change in body weight from baseline [Week 40]
Proportion of subjects with weight loss ≥5% from baseline [Week 40]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009287	Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Ji L, The lancet. Diabetes & endocrinology	2025	Randomized trial	PMID 40555243 DOI	cites ClinicalTrials.gov:NCT05813795; registry reference DERIVED:40555243